Max E Seaton1, Brodie A Parent, Ravi F Sood, Mark M Wurfel, Lara A Muffley, Grant E O'Keefe, Nicole S Gibran. 1. *Harborview Department of Surgery, University of Washington Medical Center, Seattle, Washington†Department of Surgery, University of Maryland Medical Center, Baltimore, Maryland‡Harborview Department of Medicine, University of Washington Medical Center, Seattle, Washington.
Abstract
OBJECTIVE: The aim of the study was to determine if melanocortin-1 receptor (MC1R) single nucleotide polymorphisms (SNPs) are associated with complicated sepsis after trauma. BACKGROUND: Nosocomial infections are an important cause of morbidity and mortality after trauma. Several SNPs in inflammation-related genes have been associated with sepsis. MC1R is an anti-inflammatory mediator that may be involved in the immune response after trauma. PATIENTS AND METHODS: We genotyped eight common MC1R SNPs in genomic DNA from subjects enrolled in a previously reported prospective cohort study. Subjects were adult trauma patients admitted to the intensive care unit at a Level 1 trauma center (2003-2005). RESULTS: A total of 1,246 subjects were included in the analysis. The majority were male (70%), severely injured (81%), and injured by a blunt mechanism (89%). Forty percent developed sepsis, and 23% developed complicated sepsis, which was defined as sepsis with organ dysfunction. In logistic regression analysis, with adjustments for age, sex, body mass index, injury severity score, red blood cell transfusion requirement, and mechanism of injury, the MC1RR163Q variant (rs885479) was associated with a lower risk of developing complicated sepsis (adjusted odds ratio [ORadj] = 0.48, 95% confidence interval [CI]: 0.28-0.81, P = 0.006). In a subgroup of 511 subjects with genome-wide SNP data, the association between the MC1RR163Q variant and complicated sepsis remained significant after adjusting for genetic substructure (by principal components) and the above clinical factors (ORadj = 0.30, 95% CI: 0.13-0.70, P = 0.005). CONCLUSIONS: MC1RR163Q is associated with a lower risk of complicated sepsis after trauma. Therapeutic targeting of MC1R may be beneficial for trauma patients at risk for complicated sepsis.
OBJECTIVE: The aim of the study was to determine if melanocortin-1 receptor (MC1R) single nucleotide polymorphisms (SNPs) are associated with complicated sepsis after trauma. BACKGROUND:Nosocomial infections are an important cause of morbidity and mortality after trauma. Several SNPs in inflammation-related genes have been associated with sepsis. MC1R is an anti-inflammatory mediator that may be involved in the immune response after trauma. PATIENTS AND METHODS: We genotyped eight common MC1R SNPs in genomic DNA from subjects enrolled in a previously reported prospective cohort study. Subjects were adult traumapatients admitted to the intensive care unit at a Level 1 trauma center (2003-2005). RESULTS: A total of 1,246 subjects were included in the analysis. The majority were male (70%), severely injured (81%), and injured by a blunt mechanism (89%). Forty percent developed sepsis, and 23% developed complicated sepsis, which was defined as sepsis with organ dysfunction. In logistic regression analysis, with adjustments for age, sex, body mass index, injury severity score, red blood cell transfusion requirement, and mechanism of injury, the MC1RR163Q variant (rs885479) was associated with a lower risk of developing complicated sepsis (adjusted odds ratio [ORadj] = 0.48, 95% confidence interval [CI]: 0.28-0.81, P = 0.006). In a subgroup of 511 subjects with genome-wide SNP data, the association between the MC1RR163Q variant and complicated sepsis remained significant after adjusting for genetic substructure (by principal components) and the above clinical factors (ORadj = 0.30, 95% CI: 0.13-0.70, P = 0.005). CONCLUSIONS: MC1RR163Q is associated with a lower risk of complicated sepsis after trauma. Therapeutic targeting of MC1R may be beneficial for traumapatients at risk for complicated sepsis.
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Crit Care Med Date: 2003-04 Impact factor: 7.598
Authors: Carl A Anderson; Fredrik H Pettersson; Geraldine M Clarke; Lon R Cardon; Andrew P Morris; Krina T Zondervan Journal: Nat Protoc Date: 2010-08-26 Impact factor: 13.491
Authors: N F Box; D L Duffy; R E Irving; A Russell; W Chen; L R Griffyths; P G Parsons; A C Green; R A Sturm Journal: J Invest Dermatol Date: 2001-02 Impact factor: 8.551
Authors: Callie M Thompson; Tarah D Holden; Gail Rona; Balaji Laxmanan; R Anthony Black; Grant E OʼKeefe; Mark M Wurfel Journal: Ann Surg Date: 2014-01 Impact factor: 12.969
Authors: Estelle A Wall; Joelle R Zavzavadjian; Mi Sook Chang; Baljinder Randhawa; Xiaocui Zhu; Robert C Hsueh; Jamie Liu; Adrienne Driver; Xiaoyan Robert Bao; Paul C Sternweis; Melvin I Simon; Iain D C Fraser Journal: Sci Signal Date: 2009-06-16 Impact factor: 8.192
Authors: Ravi F Sood; Anne M Hocking; Lara A Muffley; Maricar Ga; Shari Honari; Alexander P Reiner; Ali Rowhani-Rahbar; Nicole S Gibran Journal: J Invest Dermatol Date: 2015-06-01 Impact factor: 8.551
Authors: Maria Cohen; Ashley J Lamparello; Lukas Schimunek; Fayten El-Dehaibi; Rami A Namas; Yan Xu; A Murat Kaynar; Timothy R Billiar; Yoram Vodovotz Journal: Shock Date: 2020-03 Impact factor: 3.533
Authors: Chongxu Zhang; Stephanie Chery; Aaron Lazerson; Norman H Altman; Robert Jackson; Greg Holt; Michael Campos; Andrew V Schally; Mehdi Mirsaeidi Journal: Sci Rep Date: 2020-04-29 Impact factor: 4.379
Authors: Jing Zhao; Liwei Jiang; Mayuko Uehara; Naima Banouni; Basmah S Al Dulaijan; Jamil Azzi; Takaharu Ichimura; Xiaofei Li; Petr Jarolim; Paolo Fiorina; Stefan G Tullius; Joren C Madsen; Vivek Kasinath; Reza Abdi Journal: JCI Insight Date: 2021-07-08